{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:52:03Z","timestamp":1793109123699,"version":"4.5.0"},"reference-count":39,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Combined oral contraceptives (COCs) are contraindicated in migraine with aura due to stroke risk, and some hormone therapy for menopause guidelines recommend caution in this population. However, this guidance is informed by sparse or older evidence reflective of higher doses than typically prescribed today. This study aimed to describe modern\u2010day utilization of COCs and hormone therapy among female individuals with migraine with aura from 2000 to 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using United Kingdom medical record data, this study evaluated the use of COCs and progestogen\u2010only pills (POPs) among reproductive\u2010age individuals and hormone therapy among post\u2010reproductive age individuals, before and after migraine with aura diagnosis. Post\u2010diagnosis medication utilization was described relative to baseline characteristics and pre\u2010diagnosis use of each medication, overall and longitudinally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 142\u2009867 individuals of reproductive age, 84\u2009374 (59%) used oral contraceptives on or after migraine with aura diagnosis, predominantly POPs (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200975\u2009823, 53% of those with any oral contraceptive) over COCs (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921\u2009968, 15%). Most oral contraceptive users in the year pre\u2010diagnosis used COCs (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200936\u2009909\/56760, 66%). Among 46\u2009913 individuals of post\u2010reproductive age, 20\u2009990 (45%) had a prescription for hormone therapy after migraine with aura diagnosis, with transdermal formulations used increasingly over calendar time.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Utilization of COCs declined but did not fully cease after migraine with aura diagnosis. Post\u2010diagnosis utilization of hormone therapy for menopause was common. Given this utilization among individuals with migraine with aura, high\u2010quality evidence quantifying the risk of stroke associated with modern\u2010day use of these medications in this population is needed to inform patient and provider decision making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.70266","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:04:17Z","timestamp":1763132657000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Utilization of Oral Contraceptives and Hormone Therapy for Menopause Among Female Individuals With Migraine With Aura: A Descriptive Study"],"prefix":"10.1002","volume":"34","author":[{"given":"Liza R.","family":"Gibbs","sequence":"first","affiliation":[{"name":"Department of Epidemiology Boston University School of Public Health  Boston Massachusetts USA"},{"name":"Aetion, a Datavant Company  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Epidemiology Boston University School of Public Health  Boston Massachusetts USA"},{"name":"Department of Global Health Boston University School of Public Health  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo J.","family":"Aparicio","sequence":"additional","affiliation":[{"name":"Avedisian School of Medicine Boston University Chobanian  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2215-1067","authenticated-orcid":false,"given":"Susan","family":"Jick","sequence":"additional","affiliation":[{"name":"Department of Epidemiology Boston University School of Public Health  Boston Massachusetts USA"},{"name":"Boston Collaborative Drug Surveillance Program  Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"StatPearls","author":"Pescador Ruschel M. A.","year":"2024"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468\u20102982.2008.01666.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2021.07.010"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010017\u20100815\u20101"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(11)70266\u20106"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102018\u2010318254"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/2053369117731172"},{"key":"e_1_2_9_9_1","volume-title":"Medical Eligibility Criteria for Contraceptive Use","author":"World Health Organization","year":"2015"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2016.6191"},{"key":"e_1_2_9_11_1","unstructured":"UK Medical Eligibility Criteria for Contraceptive Use. Published online September 1 2019 https:\/\/www.fsrh.org\/Public\/Public\/Standards\u2010and\u2010Guidance\/uk\u2010medical\u2010eligibility\u2010criteria\u2010for\u2010contraceptive\u2010use\u2010ukmec.aspx."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015\u20102236"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2630010607"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4996"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5135"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S434832"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3233\/SHTI200154"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2021.12.017"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471\u20100528.12465"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/jfprhc\u20102012\u2010100376"},{"key":"e_1_2_9_22_1","unstructured":"UK Medical Eligibility Criteria for Contraceptive Use (UKMEC). Accessed September 8 2024 https:\/\/www.fsrh.org\/Public\/Public\/Standards\u2010and\u2010Guidance\/uk\u2010medical\u2010eligibility\u2010criteria\u2010for\u2010contraceptive\u2010use\u2010ukmec.aspx."},{"key":"e_1_2_9_23_1","unstructured":"First Progestogen\u2010Only Contraceptive Pills to be Available to Purchase From Pharmacies. GOV.UK. Accessed December 14 2024 https:\/\/www.gov.uk\/government\/news\/first\u2010progesterone\u2010only\u2010contraceptive\u2010pills\u2010to\u2010be\u2010available\u2010to\u2010purchase\u2010from\u2010pharmacies."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2024.102573"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20100328(02)02914\u20102"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.gme.0000243569.70946.9d"},{"key":"e_1_2_9_27_1","unstructured":"Hormone Replacement Therapy Report. Published Online April 2024 https:\/\/wellbeingofwomen.blob.core.windows.net\/www\/documents\/Eclipse_\u2010_HRT_Report_\u2010_Pub_Apr_24_V2_1.pdf."},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471\u20100528.2002.02214.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.061559"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab011"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181875e61"},{"key":"e_1_2_9_33_1","unstructured":"NHS Hormone Replacement Therapy Prescription Prepayment Certificate (HRT PPC) | NHSBSA. Accessed April 20 2025 https:\/\/www.nhsbsa.nhs.uk\/help\u2010nhs\u2010prescription\u2010costs\/nhs\u2010hormone\u2010replacement\u2010therapy\u2010prescription\u2010prepayment\u2010certificate\u2010hrt\u2010ppc."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.6118\/jmm.20000"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.3399\/BJGPO.2022.0126"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072\u2010018\u20103370\u2010x"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2016.06.005"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2012.02.110200"},{"key":"e_1_2_9_39_1","unstructured":"H.Gobel The International Classification of Headache Disorders. ICHD\u20103. Accessed December 14 2024 https:\/\/ichd\u20103.org\/."},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/jfprhc\u20102017\u2010101728"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T08:53:41Z","timestamp":1763715221000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/pds.70266"],"URL":"https:\/\/doi.org\/10.1002\/pds.70266","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"2025-08-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70266"}}